论文部分内容阅读
为了降低膀胱癌术后复发率，联合应用BCG和IL－2膀胱内灌注32例。随访6个月～7年6个月，平均48个月。手术后1年内复发1例（3．1％），2年内复发5例（15．6％），5年内复发7例（21．9％）。结果表明，联合应用BCG和IL－2膀胱内灌注可以增强免疫治疗效果，明显地降低膀胱癌术后的复发率，同时可以减少BCG用量过大所引起的并发症。
In order to reduce the recurrence rate of bladder cancer, BCG and IL-2 were administered intravesically in 32 cases. Follow-up 6 months to 7 years and 6 months, an average of 48 months. One case (3.1%) relapsed within 1 year after operation, 5 cases (15.6%) relapsed within 2 years and 7 cases (21.9%) within 5 years. The results showed that the combined application of BCG and IL-2 intravesical instillation can enhance the effect of immunotherapy, significantly reduce the recurrence rate of bladder cancer surgery, and can reduce the complications caused by excessive use of BCG.